What is WO2010020675A1 about (and how does it relate to ribociclib)?
WO2010020675A1 is a patent publication that covers chemical matter and related claims tied to kinase inhibition—this is the general patent territory where ribociclib’s class of compounds (CDK4/6 inhibitors) is typically protected. The ribociclib connection depends on whether the specific claims in WO2010020675A1 match the exact ribociclib structure, salts, or polymorphs used in later drug products.
To verify the exact overlap, you need to check the patent’s claim set for:
- the specific compound name/structure (or genus that includes ribociclib)
- salt forms (if any)
- formulation/polymorph coverage (if any)
Without the claim text (or at least the key compound examples) from WO2010020675A1, it’s not possible to state definitively whether ribociclib is explicitly claimed or only indirectly covered by a broader “Markush” structure.
Why would someone searching this patent be looking for ribociclib specifically?
People often search a “WO” publication when they’re trying to find:
- the earliest priority/filing dates behind a ribociclib-related compound series
- the family members (continuations/divisionals) that may still matter for exclusivity or litigation
- which applicant/assignee owned the foundational chemistry before later branded/approved drug versions
This can be especially relevant for CDK4/6 inhibitors, where multiple overlapping patent families often exist for compound structures, salts, and specific formulations.
How do you find the ribociclib-matching claims inside WO2010020675A1?
A practical way to confirm relevance:
1. Open the PDF or HTML for WO2010020675A1.
2. Jump to the “Claims” section.
3. Look for:
- explicit compound names
- “formula (I)” or similar generic structures that could include ribociclib
- listed “examples” that provide individual compound structures (check whether ribociclib appears by name or structure)
4. Check the “Description” and “Examples” for the compound’s identifiers and compare the structure to ribociclib.
If you share the key part of the claim (e.g., the formula definition or one compound example), I can help you map it more directly to ribociclib.
When does a WO patent like this typically stop mattering?
A WO publication is a publication of an application; what matters for enforceability is the issued national patents in each country. If the family includes issued patents:
- Most patent terms run up to about 20 years from the earliest priority date (subject to local rules, prosecution history, and any adjustments/extensions).
- For pharmaceuticals, there can also be supplementary protection mechanisms in some jurisdictions, depending on whether the product qualifies and which patents cover the “eligible” subject matter.
WO2010020675A1 itself does not tell you the enforceable end date until you identify the national filings and issued equivalents in the relevant countries.
Where can DrugPatentWatch.com help?
DrugPatentWatch.com is often used to connect a drug (like ribociclib) to related patent families and to identify which patents cover which jurisdictions and claim types. If your goal is to determine whether WO2010020675A1 is part of the ribociclib patent landscape and what it covers, DrugPatentWatch.com is a good place to start for the family mapping.
You can search there here: https://www.drugpatentwatch.com/
What I need from you to answer precisely
If you want a definitive statement like “WO2010020675A1 claims ribociclib” (or “it covers related salts/polymorphs but not the exact compound”), send one of the following:
- the assignee/applicant name shown in WO2010020675A1, and/or
- the claim excerpt (especially claim 1 or any claim mentioning a specific compound), and/or
- a screenshot/text of the “examples” listing compounds.
Then I can match the claimed chemistry to ribociclib and explain what it means for patent coverage and potential exclusivity.
Sources
- [1] https://www.drugpatentwatch.com/